Filing Coverage: Flagship Ventures Fund 2007 Just Disclosed New Eleven Biotherapeutics, Inc Position

Filing Coverage: Flagship Ventures Fund 2007 Just Disclosed New Eleven Biotherapeutics, Inc Position

The New Flagship Ventures Fund 2007 Holding in Eleven Biotherapeutics, Inc

Flagship Ventures Fund 2007 filed with the SEC SC 13D/A form for Eleven Biotherapeutics, Inc. The form can be accessed here: 000119312516780847. As reported in Flagship Ventures Fund 2007’s form, the filler as of late owns 5.8% or 1,400,944 shares of the Health Care–company.

Eleven Biotherapeutics, Inc stake is a new one for the and it was filed because of activity on November28, 2016. We feel this shows Flagship Ventures Fund 2007’s positive view for the stock.

Eleven Biotherapeutics, Inc Institutional Sentiment

Latest Security and Exchange filings show 28 investors own Eleven Biotherapeutics, Inc. The institutional ownership in Q3 2015 is low, at 76.73% of the outstanding shares. This is increased by 4426014 the total institutional shares. 18599775 were the shares owned by these institutional investors. In total 6 funds opened new Eleven Biotherapeutics, Inc stakes, 8 increased stakes. There were 16 that closed positions and 6 reduced them.

2 managers had the stock in their top Ten. Notable investors are: Flagship Ventures 2007 General Partner Llc..

Rotella Capital Management Inc is an institutional investor bullish on Eleven Biotherapeutics, Inc, owning 190947 shares as of Q3 2015 for 0.15% of its portfolio. Jeremy Green Redmile Group Llc owns 848351 shares or 0.04% of its portfolio. MA Third Rock Ventures Llc have 1.09% of their stock portfolio for 4841591 shares. Further, Sarissa Capital Management Lp reported stake worth 0.02% of its US stock portfolio. The MA Flagship Ventures 2007 General Partner Llc owns 1907008 shares. Eleven Biotherapeutics, Inc is 2.89% of the manager’s US portfolio.

Business Profile

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.

Insitutional Activity: The institutional sentiment increased to 2.29 in Q2 2016. Its up 1.29, from 1 in 2016Q1. The ratio increased, as 5 funds sold all Eleven Biotherapeutics Inc shares owned while 4 reduced positions. 5 funds bought stakes while 4 increased positions. They now own 2.51 million shares or 36.45% more from 1.84 million shares in 2016Q1.

Grp One Trading Limited Partnership, a Illinois-based fund reported 600 shares. Kcg Holding Incorporated has invested 0% of its portfolio in Eleven Biotherapeutics Inc (NASDAQ:EBIO). Citigroup holds 600 shares or 0% of its portfolio. Bancorp Of Ny Mellon accumulated 0% or 67,483 shares. Guggenheim Limited Liability Company has 0% invested in the company for 10,331 shares. Royal Commercial Bank Of Canada last reported 0% of its portfolio in the stock. Moreover, Morgan Stanley has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 1,503 shares. Bank & Trust Of America Corporation De last reported 0% of its portfolio in the stock. Moreover, Geode Capital Management Limited Liability has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 46,637 shares. Fiduciary Tru Co holds 0% or 10,000 shares in its portfolio. Reilly Financial Advisors Lc holds 0% or 100 shares in its portfolio. Renaissance Techs Limited Liability Corp last reported 0% of its portfolio in the stock. Moreover, Blackrock Fund Advsr has 0% invested in Eleven Biotherapeutics Inc (NASDAQ:EBIO) for 1,624 shares. Two Sigma Secs Limited Liability Co has 0.02% invested in the company for 25,428 shares. Blackrock Institutional Tru Na holds 0% or 149,618 shares in its portfolio.

Analysts await Eleven Biotherapeutics Inc (NASDAQ:EBIO) to report earnings on March, 23.

About 349,453 shares traded hands. Eleven Biotherapeutics Inc (NASDAQ:EBIO) has risen 142.71% since April 27, 2016 and is uptrending. It has outperformed by 137.48% the S&P500.

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The company has a market cap of $52.36 million. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. It currently has negative earnings. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema and uveitis.

Eleven Biotherapeutics Inc (NASDAQ:EBIO) Ratings Coverage

Out of 2 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 0 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 0 are positive. $8.35 is the highest target while $0.40 is the lowest. The $4.38 average target is 96.41% above today’s ($2.23) stock price. Eleven Biotherapeutics has been the topic of 4 analyst reports since August 15, 2015 according to StockzIntelligence Inc. Citigroup downgraded the stock to “Neutral” rating in Tuesday, January 19 report. Citigroup maintained Eleven Biotherapeutics Inc (NASDAQ:EBIO) on Wednesday, March 16 with “Neutral” rating. On Tuesday, January 19 the stock rating was downgraded by Leerink Swann to “Market Perform”. Leerink Swann maintained the shares of EBIO in a report on Saturday, August 15 with “Outperform” rating.

According to Zacks Investment Research, “Eleven Biotherapeutics, Inc. is engaged in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its principal preclinical product candidate consist of EBI-005, a novel IL-1 receptor antagonist for the topical treatment of dry eye disease and allergic conjunctivitis, EBI-029, a novel inhibitor of the cytokine IL-6 for the treatment of certain retinal diseases, such as DME and EBI-028, a novel inhibitor of the cytokine IL-17 for the treatment of uveitis. Eleven Biotherapeutics, Inc. is based in Cambridge, United States.”

EBIO Company Profile

Eleven Biotherapeutics, Inc., incorporated on February 25, 2008, is a preclinical-stage biopharmaceutical company. The Firm applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment